Percutaneous intracavitary treatment of pulmonary aspergilloma-clinical efficacy and prognosis

F. Furuse, Y. Nakanishi, H. Kotoh, H. Inoue, J. Yatsunami, T. Ikeda, N. Hara

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We have performed percutaneous intracavitary treatment with anti-fungal reagents in 8 patients with pulmonary aspergilloma (6 males and 2 female) over the past decade. Ages ranged from 43 to 84 years old. All of the patients had underlying lung diseases, seven having old pulmonary tuberculosis and one pneumoconiosis. Five patients had a history of hemoptysis or hemosputum. Amphotericin B (AMPH) was injected daily in 5 patients, Fulconazol (FCZ) in 2 patients, and both in the remaining patient. For AMPH, maximal dose, total dose, and treatment duration were 20 to 50 mg, 285 to 1560 mg, and one to 7.5 months, respectively, and for FCZ, 20 to 30 mg, 450 to 1600 mg, 3 weeks to 4 months, respectively. At the end of treatment, fungus balls disappeared in 2 patients, decreased in size in 3 patients and were unchanged in 3 patients. After follow up periods of 7 months through 6.5 years, 5 of 6 patients remained in roentogenologically better condition than before treatment, and 3 of 5 patients with episodes of hemoptysis or hemosputum have not since had airway bleeding. The prognosis of the other two patients are unknown, since they died of other diseases before this survey. One patient had aspergillus empyema 7 months after treatment. There were no serious side effects or complications directly related to treatment. It was suggested that continuous percutaneous intracavitary treatment with anti-fungal reagents is safe and effective for inoperable patients with aspergilloma.

Original languageEnglish
Pages (from-to)538-543
Number of pages6
JournalJapanese Journal of Thoracic Diseases
Volume32
Issue number6
Publication statusPublished - Jan 1 1994

Fingerprint

Lung
Therapeutics
Hemoptysis
Amphotericin B
Pneumoconiosis
Empyema
Aspergillus
Pulmonary Tuberculosis
Lung Diseases
Fungi
Hemorrhage

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Furuse, F., Nakanishi, Y., Kotoh, H., Inoue, H., Yatsunami, J., Ikeda, T., & Hara, N. (1994). Percutaneous intracavitary treatment of pulmonary aspergilloma-clinical efficacy and prognosis. Japanese Journal of Thoracic Diseases, 32(6), 538-543.

Percutaneous intracavitary treatment of pulmonary aspergilloma-clinical efficacy and prognosis. / Furuse, F.; Nakanishi, Y.; Kotoh, H.; Inoue, H.; Yatsunami, J.; Ikeda, T.; Hara, N.

In: Japanese Journal of Thoracic Diseases, Vol. 32, No. 6, 01.01.1994, p. 538-543.

Research output: Contribution to journalArticle

Furuse, F, Nakanishi, Y, Kotoh, H, Inoue, H, Yatsunami, J, Ikeda, T & Hara, N 1994, 'Percutaneous intracavitary treatment of pulmonary aspergilloma-clinical efficacy and prognosis', Japanese Journal of Thoracic Diseases, vol. 32, no. 6, pp. 538-543.
Furuse F, Nakanishi Y, Kotoh H, Inoue H, Yatsunami J, Ikeda T et al. Percutaneous intracavitary treatment of pulmonary aspergilloma-clinical efficacy and prognosis. Japanese Journal of Thoracic Diseases. 1994 Jan 1;32(6):538-543.
Furuse, F. ; Nakanishi, Y. ; Kotoh, H. ; Inoue, H. ; Yatsunami, J. ; Ikeda, T. ; Hara, N. / Percutaneous intracavitary treatment of pulmonary aspergilloma-clinical efficacy and prognosis. In: Japanese Journal of Thoracic Diseases. 1994 ; Vol. 32, No. 6. pp. 538-543.
@article{8fea8f98f0a94dcb870b3dac0de05fac,
title = "Percutaneous intracavitary treatment of pulmonary aspergilloma-clinical efficacy and prognosis",
abstract = "We have performed percutaneous intracavitary treatment with anti-fungal reagents in 8 patients with pulmonary aspergilloma (6 males and 2 female) over the past decade. Ages ranged from 43 to 84 years old. All of the patients had underlying lung diseases, seven having old pulmonary tuberculosis and one pneumoconiosis. Five patients had a history of hemoptysis or hemosputum. Amphotericin B (AMPH) was injected daily in 5 patients, Fulconazol (FCZ) in 2 patients, and both in the remaining patient. For AMPH, maximal dose, total dose, and treatment duration were 20 to 50 mg, 285 to 1560 mg, and one to 7.5 months, respectively, and for FCZ, 20 to 30 mg, 450 to 1600 mg, 3 weeks to 4 months, respectively. At the end of treatment, fungus balls disappeared in 2 patients, decreased in size in 3 patients and were unchanged in 3 patients. After follow up periods of 7 months through 6.5 years, 5 of 6 patients remained in roentogenologically better condition than before treatment, and 3 of 5 patients with episodes of hemoptysis or hemosputum have not since had airway bleeding. The prognosis of the other two patients are unknown, since they died of other diseases before this survey. One patient had aspergillus empyema 7 months after treatment. There were no serious side effects or complications directly related to treatment. It was suggested that continuous percutaneous intracavitary treatment with anti-fungal reagents is safe and effective for inoperable patients with aspergilloma.",
author = "F. Furuse and Y. Nakanishi and H. Kotoh and H. Inoue and J. Yatsunami and T. Ikeda and N. Hara",
year = "1994",
month = "1",
day = "1",
language = "English",
volume = "32",
pages = "538--543",
journal = "Respiratory Investigation",
issn = "2212-5345",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Percutaneous intracavitary treatment of pulmonary aspergilloma-clinical efficacy and prognosis

AU - Furuse, F.

AU - Nakanishi, Y.

AU - Kotoh, H.

AU - Inoue, H.

AU - Yatsunami, J.

AU - Ikeda, T.

AU - Hara, N.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - We have performed percutaneous intracavitary treatment with anti-fungal reagents in 8 patients with pulmonary aspergilloma (6 males and 2 female) over the past decade. Ages ranged from 43 to 84 years old. All of the patients had underlying lung diseases, seven having old pulmonary tuberculosis and one pneumoconiosis. Five patients had a history of hemoptysis or hemosputum. Amphotericin B (AMPH) was injected daily in 5 patients, Fulconazol (FCZ) in 2 patients, and both in the remaining patient. For AMPH, maximal dose, total dose, and treatment duration were 20 to 50 mg, 285 to 1560 mg, and one to 7.5 months, respectively, and for FCZ, 20 to 30 mg, 450 to 1600 mg, 3 weeks to 4 months, respectively. At the end of treatment, fungus balls disappeared in 2 patients, decreased in size in 3 patients and were unchanged in 3 patients. After follow up periods of 7 months through 6.5 years, 5 of 6 patients remained in roentogenologically better condition than before treatment, and 3 of 5 patients with episodes of hemoptysis or hemosputum have not since had airway bleeding. The prognosis of the other two patients are unknown, since they died of other diseases before this survey. One patient had aspergillus empyema 7 months after treatment. There were no serious side effects or complications directly related to treatment. It was suggested that continuous percutaneous intracavitary treatment with anti-fungal reagents is safe and effective for inoperable patients with aspergilloma.

AB - We have performed percutaneous intracavitary treatment with anti-fungal reagents in 8 patients with pulmonary aspergilloma (6 males and 2 female) over the past decade. Ages ranged from 43 to 84 years old. All of the patients had underlying lung diseases, seven having old pulmonary tuberculosis and one pneumoconiosis. Five patients had a history of hemoptysis or hemosputum. Amphotericin B (AMPH) was injected daily in 5 patients, Fulconazol (FCZ) in 2 patients, and both in the remaining patient. For AMPH, maximal dose, total dose, and treatment duration were 20 to 50 mg, 285 to 1560 mg, and one to 7.5 months, respectively, and for FCZ, 20 to 30 mg, 450 to 1600 mg, 3 weeks to 4 months, respectively. At the end of treatment, fungus balls disappeared in 2 patients, decreased in size in 3 patients and were unchanged in 3 patients. After follow up periods of 7 months through 6.5 years, 5 of 6 patients remained in roentogenologically better condition than before treatment, and 3 of 5 patients with episodes of hemoptysis or hemosputum have not since had airway bleeding. The prognosis of the other two patients are unknown, since they died of other diseases before this survey. One patient had aspergillus empyema 7 months after treatment. There were no serious side effects or complications directly related to treatment. It was suggested that continuous percutaneous intracavitary treatment with anti-fungal reagents is safe and effective for inoperable patients with aspergilloma.

UR - http://www.scopus.com/inward/record.url?scp=0028132845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028132845&partnerID=8YFLogxK

M3 - Article

C2 - 8089940

AN - SCOPUS:0028132845

VL - 32

SP - 538

EP - 543

JO - Respiratory Investigation

JF - Respiratory Investigation

SN - 2212-5345

IS - 6

ER -